MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jinf.2025.106510

Медицинская библиотека · The Journal of infection · 2025

Monitoring the emergence of resistance with sotrovimab in immunocompromised patients with COVID-19: LUNAR study.

Breuer Judith, Drysdale Myriam, Walker Jill, Han Jennifer, Aylott Alicia, Van Dyke Melissa K, Birch Helen J, McKie Elizabeth, Jordan William, Gemzoe Kim, Gillespie Iain A, Bethune Claire, Williams Charlotte A, Underwood Jonathan, Goodman Anna L, Brown Michael, Brown Julianne R, Williams Rachel, Bernal Luz Marina Martin, Buggiotti Laura, Gkrania-Klotsas Effrossyni, Green Clara, Hunter Ewan, Miller Charles, Skingsley Andrew, Lowe David M

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVES

To assess outcomes in sotrovimab-treated immunocompromised patients in the United Kingdom.

METHODS

Multicenter, prospective, observational, descriptive study in immunocompromised, non-hospitalized adults infected with SARS-CoV-2 who received intravenous sotrovimab 500 mg as standard-of-care (July 1, 2022-June 30, 2023; Omicron predominance). Virology analyses included determination of SARS-CoV-2 viral load, spike sequencing, and determination of amino-acid substitutions in the spike protein and sotrovimab epitope.

RESULTS

The proportion of participants (N = 217) with undetectable SARS-CoV-2 RNA was 25.1% at day 7, 65.8% at day 14%, and 83.5% at day 28. Of 156 participants with paired sequences, 101 (64.7%) and 47 (30.1%) had treatment-emergent substitutions at >50% allelic frequency in the spike protein and sotrovimab epitope, respectively, at any post-baseline timepoint. Ten treatment-emergent substitutions (at positions 337, 340, and 356) were identified in the epitope at >50% allelic frequency. Five of 18 (27.8%) participants with, versus 22/30 (73.3%) of those without, treatment-emergent epitope substitutions at day 14 achieved undetectable SARS-CoV-2 RNA levels at day 28.

CONCLUSIONS

In this immunocompromised population infected with SARS-CoV-2 who received early treatment with sotrovimab, most participants (83.5%) experienced substantial viral load reductions by day 28. Treatment-emergent substitutions occurred in the sotrovimab epitope, including substitutions known to reduce susceptibility in vitro. Several treatment-emergent substitutions were associated with viral persistence.

Для цитирования: Breuer Judith, Drysdale Myriam, Walker Jill, Han Jennifer, Aylott Alicia, Van Dyke Melissa K, Birch Helen J, McKie Elizabeth, Jordan William, Gemzoe Kim, Gillespie Iain A, Bethune Claire, Williams Charlotte A, Underwood Jonathan, Goodman Anna L, Brown Michael, Brown Julianne R, Williams Rachel, Bernal Luz Marina Martin, Buggiotti Laura, Gkrania-Klotsas Effrossyni, Green Clara, Hunter Ewan, Miller Charles, Skingsley Andrew, Lowe David M. Monitoring the emergence of resistance with sotrovimab in immunocompromised patients with COVID-19: LUNAR study.. The Journal of infection. 2025. DOI: 10.1016/j.jinf.2025.106510.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.